Dudediligence.

Invivyd, Inc

IVVDNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

294.8M

on 2026-06-30, from 119.2M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

100M200M300MMar2024JunSepDecMar2025JunSep$0.52Dec$2.50Mar2026Jun

Newest

$350.0M

S-3 of 2025-10-02. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗

$75.0M

Cantor Fitzgerald, agreement of 2023-12-22. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

6.82M

Warrants of every class as tagged in the XBRL facts on 2024-09-30, exercise price $3.48. 10-Q ↗

Cash

5.9 quarters

$160.1M on 2026-06-30 ÷ $27.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-11-17Public offering incl. 6.00M pre-funded50,000,000$2.50$125.0M424B5 ↗
2025-08-20Public offering incl. 21.34M pre-funded96,153,846$0.52$50.0M424B5 ↗

Also on file: up to $30.0M term loan agreed 2025-04-21 8-K ↗